JP2018523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523676A5
JP2018523676A5 JP2018508149A JP2018508149A JP2018523676A5 JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5 JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5
Authority
JP
Japan
Prior art keywords
histidine
hcl
aniflorumab
polysorbate
trehalose dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018508149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523676A (ja
JP6720293B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/047506 external-priority patent/WO2017031288A1/en
Publication of JP2018523676A publication Critical patent/JP2018523676A/ja
Publication of JP2018523676A5 publication Critical patent/JP2018523676A5/ja
Application granted granted Critical
Publication of JP6720293B2 publication Critical patent/JP6720293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018508149A 2015-08-19 2016-08-18 安定な抗ｉｆｎａｒ１製剤 Active JP6720293B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
US62/207,164 2015-08-19
PCT/US2016/047506 WO2017031288A1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020104494A Division JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤

Publications (3)

Publication Number Publication Date
JP2018523676A JP2018523676A (ja) 2018-08-23
JP2018523676A5 true JP2018523676A5 (https=) 2020-04-23
JP6720293B2 JP6720293B2 (ja) 2020-07-08

Family

ID=58052002

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018508149A Active JP6720293B2 (ja) 2015-08-19 2016-08-18 安定な抗ｉｆｎａｒ１製剤
JP2020104494A Active JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤
JP2022031581A Pending JP2022066345A (ja) 2015-08-19 2022-03-02 安定な抗ｉｆｎａｒ１製剤
JP2024140769A Pending JP2024161043A (ja) 2015-08-19 2024-08-22 安定な抗ｉｆｎａｒ１製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020104494A Active JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤
JP2022031581A Pending JP2022066345A (ja) 2015-08-19 2022-03-02 安定な抗ｉｆｎａｒ１製剤
JP2024140769A Pending JP2024161043A (ja) 2015-08-19 2024-08-22 安定な抗ｉｆｎａｒ１製剤

Country Status (23)

Country Link
US (1) US10125195B2 (https=)
EP (3) EP3769781B1 (https=)
JP (4) JP6720293B2 (https=)
KR (4) KR20240090616A (https=)
CN (1) CN107921109B (https=)
AU (3) AU2016308262C1 (https=)
CA (1) CA2995222C (https=)
CY (2) CY1123657T1 (https=)
DK (2) DK3337502T3 (https=)
ES (2) ES2818229T3 (https=)
FI (1) FI3769781T3 (https=)
HR (2) HRP20230463T1 (https=)
HU (2) HUE051862T2 (https=)
IL (1) IL257279B2 (https=)
LT (2) LT3337502T (https=)
PL (2) PL3769781T3 (https=)
PT (2) PT3337502T (https=)
RS (2) RS64263B1 (https=)
RU (1) RU2731737C2 (https=)
SG (1) SG10202106970XA (https=)
SI (2) SI3337502T1 (https=)
SM (2) SMT202000483T1 (https=)
WO (1) WO2017031288A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP4494712A3 (en) * 2019-11-11 2025-03-26 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4157873A2 (en) * 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
WO2021260193A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
US20220193238A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
CA3216390A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of cutaneous lupus erythematous
CA3216395A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
CN120392997A (zh) * 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
IL308128A (en) * 2021-05-12 2023-12-01 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
KR20240038773A (ko) 2021-07-27 2024-03-25 아스트라제네카 아베 루푸스의 치료
JP2024536320A (ja) * 2021-10-04 2024-10-04 アストラゼネカ・アクチエボラーグ ループスの処置
EP4422674A4 (en) * 2021-10-29 2025-09-17 Intas Pharmaceuticals Ltd Stable lyophilized formulation of an anti-alpha 4beta7 antibody
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2024009205A1 (en) * 2022-07-06 2024-01-11 Intas Pharmaceuticals Ltd. STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY
CN120344259A (zh) 2022-10-13 2025-07-18 阿斯利康(瑞典)有限公司 狼疮的治疗
AU2024277546A1 (en) 2023-05-19 2026-01-15 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CL2007003583A1 (es) 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
KR20160070165A (ko) * 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CA2849192C (en) 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
EP2997036B1 (en) 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
JP2017502922A (ja) * 2013-10-29 2017-01-26 アルブミディクス アクティーゼルスカブ 抗体組成物
CA2959571A1 (en) 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija

Similar Documents

Publication Publication Date Title
JP2018523676A5 (https=)
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EP3316928A4 (en) AUTOMATIC INJECTORS FOR THE ADMINISTRATION OF A MEDICAMENT IN A PREPARED SYRINGE
HRP20211371T1 (hr) Stabilne, vodene formulacije protutijela
EA201792591A1 (ru) Фармацевтические препараты
JP2015057451A5 (https=)
HRP20221263T1 (hr) Ciklički di-nukleotidni spojevi i postupci uporabe
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
JP2015110588A5 (https=)
AR092401A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr)
EA201891606A1 (ru) Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
HRP20191137T1 (hr) Formulacije otopina konstruiranih anti-il-23p19 antitijela
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
JP2016510326A5 (https=)
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
JP2016515623A5 (https=)
TW201613557A (en) Stable aqueous recombinant protein formulations
EA201890788A1 (ru) Препараты оланзапина с замедленным высвобождением
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
JP2016534062A5 (https=)
JP2014058509A5 (https=)